A detailed history of Algert Global LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 10,080 shares of KROS stock, worth $181,440. This represents 0.02% of its overall portfolio holdings.

Number of Shares
10,080
Previous 15,700 35.8%
Holding current value
$181,440
Previous $717,000 18.41%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$41.68 - $58.07 $234,241 - $326,353
-5,620 Reduced 35.8%
10,080 $585,000
Q2 2024

Aug 14, 2024

BUY
$44.58 - $66.89 $67,092 - $100,669
1,505 Added 10.6%
15,700 $717,000
Q1 2024

May 14, 2024

BUY
$41.26 - $70.48 $146,885 - $250,908
3,560 Added 33.47%
14,195 $940,000
Q3 2023

Nov 13, 2023

SELL
$31.57 - $43.02 $188,157 - $256,399
-5,960 Reduced 35.91%
10,635 $339,000
Q1 2023

May 12, 2023

BUY
$41.44 - $59.32 $687,696 - $984,415
16,595 New
16,595 $709,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $464M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.